We describe the design of the phase IIb/III trial of TRK-100STP , CASSIOPEIR ( CRF Asian Study with Oral PGI2 derivative for Evaluating Improvement of Renal function ) conducted in approximately 160 centers in China , Hong Kong , Japan , Malaysia , Republic of Korea , Taiwan , and Thailand .